{
    "clinical_study": {
        "@rank": "66935", 
        "arm_group": [
            {
                "arm_group_label": "Exforge tab. 10/160mg", 
                "arm_group_type": "Active Comparator", 
                "description": "amlodipine besylate (10mg as amlodipine)\nvalsartan 160mg"
            }, 
            {
                "arm_group_label": "Lodivixx tab. 5/160mg", 
                "arm_group_type": "Experimental", 
                "description": "S-amlodipine nicotinate (5mg as S-amlodipine)\nvalsartan 160mg"
            }
        ], 
        "brief_summary": {
            "textblock": "To assess the pharmacokinetic characteristics of Lodivixx tab.5/160mg in healthy male\n      subjects\n\n        -  PK parameter evaluation\n\n        -  Safety profile evaluation"
        }, 
        "brief_title": "Clinical Trial to Assess the Pharmacokinetic Characteristics of Lodivixx Tab. 5/160mg in Healthy Male Subjects", 
        "completion_date": {
            "#text": "December 2012", 
            "@type": "Actual"
        }, 
        "condition": "Healthy Male Subjects", 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Years 20-45\n\n          -  Body weight \u2265 50kg and 18 \u2264 BMI \u2264 29kg/m2\n\n          -  volunteer\n\n        Exclusion Criteria:\n\n          -  Subject with serious active cardiovascular, respiratory, hepatologic, renal,\n             hematologic, gastrointestinal, immunologic, dermal, neurologic, or psychological\n             disease or history of such disease\n\n          -  Subject with symptoms of acute disease within 28days prior to study medication dosing\n\n          -  Subject with known for history which affect on the absorption, distribution,\n             metabolism or excretion of drug\n\n          -  Subject with clinically significant active chronic disease\n\n          -  Subject with any of the following conditions in laboratory test i. AST(sGOT) or\n             ALT(sGPT) > Upper normal limit \u00d7 1.5 ii. Total bilirubin > Upper normal limit \u00d7 1.5\n             iii. renal failure with Creatinine clearance < 50mL/min\n\n          -  Clinically significant hypotension when screening period (SBP < 100mmHg, DBP <\n             60mmHg)\n\n          -  Positive test results for HBs Ab, HCV Ab, Syphilis regain test\n\n          -  Use of any prescription medication within 14 days prior to study medication dosing\n\n          -  Use of any medication such as over-the-counter medication including oriental\n             medication within 7 days prior to study medication dosing\n\n          -  Subject with clinically significant allergic disease (except for mild allergic\n             rhinitis and mild allergic dermatitis that are not needed to administer drug)\n\n          -  Subject with known for hypersensitivity reaction to S-amlodipine, amlodipine and\n             valsartan and dihydropyridine derivatives\n\n          -  Subject who is not able to taking the institutional standard meal\n\n          -  Subjects with whole blood donation within 60days, component blood donation within\n             20days\n\n          -  Subjects receiving blood transfusion within 30days prior to study medication dosing\n\n          -  Participation in any clinical investigation within 60days prior to study medication\n             dosing\n\n          -  Continued excessive use of caffeine (caffeine > five cups/day),\n             alcohol(alcohol>30g/day) and severe heavy smoker (cigarette > 10 cigarettes per day)\n\n          -  Subject who has been taken meal which affect on the absorption, distribution,\n             metabolism, excretion of drug, especially grapefruit juice\n\n          -  Subject taking inducer or inhibitor of drug metabolism enzyme such as barbital within\n             28days prior to study medication dosing\n\n          -  Continued serum potassium concentration abnormal status (on baseline visit, <\n             3.5mEq/L or > 5.5mEq/L)\n\n          -  Subjects with decision of nonparticipation through investigator's review due to\n             laboratory test results or other excuse such as non-responding to request or\n             instruction by investigator"
            }, 
            "gender": "Male", 
            "healthy_volunteers": "Accepts Healthy Volunteers", 
            "maximum_age": "40 Years", 
            "minimum_age": "20 Years"
        }, 
        "enrollment": {
            "#text": "40", 
            "@type": "Actual"
        }, 
        "firstreceived_date": "July 19, 2012", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01652339", 
            "org_study_id": "HL-LDV-101"
        }, 
        "intervention": [
            {
                "arm_group_label": "Exforge tab. 10/160mg", 
                "intervention_name": "Exforge tab. 10/160mg", 
                "intervention_type": "Drug", 
                "other_name": [
                    "- amlodipine besylate", 
                    "- valsartan"
                ]
            }, 
            {
                "arm_group_label": "Lodivixx tab. 5/160mg", 
                "intervention_name": "Lodivixx tab. 5/160mg", 
                "intervention_type": "Drug", 
                "other_name": [
                    "- S-amlodipine", 
                    "- valsartan"
                ]
            }
        ], 
        "intervention_browse": {
            "mesh_term": [
                "Amlodipine", 
                "Valsartan", 
                "Amlodipine, valsartan drug combination"
            ]
        }, 
        "is_fda_regulated": "No", 
        "lastchanged_date": "March 25, 2013", 
        "location": {
            "facility": {
                "address": {
                    "city": "Busan", 
                    "country": "Korea, Republic of", 
                    "zip": "614-735"
                }, 
                "name": "Inje University Busan Paik Hospital"
            }
        }, 
        "location_countries": {
            "country": "Korea, Republic of"
        }, 
        "number_of_arms": "2", 
        "overall_official": {
            "affiliation": "Inje University", 
            "last_name": "Jae Gook Shin, MD", 
            "role": "Principal Investigator"
        }, 
        "overall_status": "Completed", 
        "oversight_info": {
            "authority": "Korea: Food and Drug Administration", 
            "has_dmc": "No"
        }, 
        "phase": "Phase 1", 
        "primary_completion_date": {
            "#text": "August 2012", 
            "@type": "Actual"
        }, 
        "primary_outcome": [
            {
                "measure": "Cmax (maximum concentration)", 
                "safety_issue": "No", 
                "time_frame": "- Valsartan evaluation : 0, 0.5, 1, 2, 3, 4, 5, 6, 8, 10, 12, 24, 36, 48hr (14 points) - S-Amlodipine : 0, 0.5, 1, 2, 3, 4, 5, 6, 8, 10, 12, 24, 36, 48, 72, 120, 168 (17 points)"
            }, 
            {
                "measure": "AUC(area under curve)", 
                "safety_issue": "No", 
                "time_frame": "- Valsartan evaluation : 0, 0.5, 1, 2, 3, 4, 5, 6, 8, 10, 12, 24, 36, 48hr (14 points) - S-Amlodipine : 0, 0.5, 1, 2, 3, 4, 5, 6, 8, 10, 12, 24, 36, 48, 72, 120, 168 (17 points)"
            }
        ], 
        "reference": {
            "PMID": "18257612", 
            "citation": "Plosker GL, Robinson DM. Amlodipine/Valsartan: fixed-dose combination in hypertension. Drugs. 2008;68(3):373-81. Review."
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01652339"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": {
            "measure": "Number of participants with adverse events", 
            "safety_issue": "Yes", 
            "time_frame": "Participants will be followed for the duration of hospital stay, an expected average of 3 days and follow-up period for maximum 6 days from the discharge"
        }, 
        "source": "Hanlim Pharm. Co., Ltd.", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Hanlim Pharm. Co., Ltd.", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "July 2012", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Crossover Assignment, Masking: Open Label", 
        "study_type": "Interventional", 
        "verification_date": "March 2013"
    }
}